The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: Results of a pre-operative study

Breast Cancer Research and Treatment

Volumn 128, Issue 3, 2011, Pages 725-734

  MacAskill, E J ^a,b,d   Bartlett, J M S ^b   Sabine, V S ^b   Faratian, D ^a   Renshaw, L ^a   White, S ^a   Campbell, F M ^b   Young, O ^a   Williams, L ^c   Thomas, J S ^a   Barber, M D ^a   Dixon, J M ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b Edinburgh Cancer Research Centre   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Everolimus; Growth factors; mTOR; Proliferation; RAD001

Indexed keywords

CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PROGESTERONE RECEPTOR; PROTEIN KINASE B; S6 KINASE;

ADULT; AGED; APOPTOSIS; ARTHRALGIA; ARTICLE; BREAST BIOPSY; BREAST CANCER; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE SEVERITY; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIGESTION; INFECTION; MASTECTOMY; MOUTH ULCER; NAUSEA; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PRURITUS; SKIN BRUISING; TREATMENT DURATION; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RIBOSOMAL PROTEIN S6 KINASES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79960843088     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0967-z     Document Type: Article

References (51)

1. J Kunz R Henriquez U Schneider, et al. 1993 Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression Cell 73 3 585 596 8387896 10.1016/0092-8674(93)90144-F 1:CAS:528:DyaK3sXks1OqtrY%3D (Pubitemid 23143356)
2. EJ Brown MW Albers TB Shin, et al. 1994 A mammalian protein targeted by G1-arresting rapamycin-receptor complex Nature 369 756 758 8008069 10.1038/369756a0 1:CAS:528:DyaK2cXlsFSiu74%3D (Pubitemid 24225367)
3. MI Chiu H Katz V Berlin 1994 RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex Proc Natl Acad Sci USA 91 12574 12578 7809080 10.1073/pnas.91.26.12574 1:CAS:528:DyaK2MXivVCrt7w%3D
4. DM Sabatini H Erdjument-Bromage M Lui P Tempst SH Snyder 1994 RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs Cell 78 35 43 7518356 10.1016/0092-8674(94)90570-3 1:CAS:528:DyaK2cXlvFOhu7Y%3D (Pubitemid 24228298)
5. CJ Sabers MM Martin GJ Brunn, et al. 1995 Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells J Biol Chem 270 2 815 822 7822316 10.1074/jbc.270.2.815 1:CAS:528:DyaK2MXjtFKrsrw%3D
6. S Chan 2004 Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer Br J Cancer 91 1420 1424 15365568 10.1038/sj.bjc.6602162 1:CAS:528:DC%2BD2cXotlCktb0%3D (Pubitemid 39486341)
7. I Vivanco CL Sawyers 2002 The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2 489 501 12094235 10.1038/nrc839 1:CAS:528:DC%2BD38XkvFKltLs%3D (Pubitemid 37328931)
8. K Inoki MN Corradetti KL Guan 2005 Dysregulation of the TSC-mTOR pathway in human disease Nat Genet 37 19 24 15624019 10.1038/ng1494 1:CAS:528: DC%2BD2cXhtFChsL3M (Pubitemid 40070934)
9. I Sansal WR Sellers 2004 The biology and clinical relevance of the PTEN tumor suppressor pathway J Clin Oncol 22 2954 2963 15254063 10.1200/JCO.2004.02. 141 1:CAS:528:DC%2BD2cXpsVWktbk%3D (Pubitemid 41079915)
10. S Vignot S Faivre D Aguirre E Raymond 2005 mTOR-targeted therapy of cancer with rapamycin derivatives Ann Oncol 16 525 537 15728109 10.1093/annonc/mdi113 1:STN:280:DC%2BD2M7kvVWmsQ%3D%3D (Pubitemid 40613318)
11. N Hay 2005 The Akt-mTOR tango and its relevance to cancer Cancer Cell 8 179 183 16169463 10.1016/j.ccr.2005.08.008 1:CAS:528:DC%2BD2MXhtV2gt7rL (Pubitemid 41317589)
12. R Loewith E Jacinto S Wullschleger, et al. 2002 Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control Mol Cell 10 457 468 12408816 10.1016/S1097-2765(02)00636-6 1:CAS:528: DC%2BD38XnvFSlt74%3D (Pubitemid 35284167)
13. DH Kim DD Sarbassov SM Ali, et al. 2002 mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery Cell 110 163 175 12150925 10.1016/S0092-8674(02)00808-5 1:CAS:528: DC%2BD38XlvV2htr4%3D (Pubitemid 34876545)
14. DD Sarbassov SM Ali DH Kim, et al. 2004 Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton Curr Biol 14 1296 1302 15268862 10.1016/j.cub.2004. 06.054 1:CAS:528:DC%2BD2cXmtVamsLs%3D (Pubitemid 38991819)
15. S Wullschleger R Loewith W Oppliger MN Hall 2005 Molecular organization of target of rapamycin complex 2 J Clin Biol 280 35 30697 30704 1:CAS:528:DC%2BD2MXpsVCmsLY%3D (Pubitemid 41291798)
16. DD Sarbassov DA Guertin SM Ali DM Sabatini 2005 Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 1098 1101 15718470 10.1126/science.1106148 1:CAS:528:DC%2BD2MXhtlSrtbY%3D (Pubitemid 40262113)
17. PE Burnett RK Barrow NA Cohen SH Snyder DM Sabatini 1998 RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1 Proc Natl Acad Sci USA 95 1432 1437 9465032 10.1073/pnas.95.4.1432 1:CAS:528:DyaK1cXht1Wqsbo%3D (Pubitemid 28103409)
18. S Wullschleger R Loewith MN Hall 2006 TOR signaling in growth and metabolism Cell 124 471 484 16469695 10.1016/j.cell.2006.01.016 1:CAS:528:DC%2BD28Xhslaqs74%3D (Pubitemid 43199434)
19. DD Sarbassov SM Ali DM Sabatini 2005 Growing roles for the mTOR pathway Curr Opin Cell Biol 17 596 603 16226444 10.1016/j.ceb.2005.09.009 1:CAS:528:DC%2BD2MXhtFyksL7F (Pubitemid 41540408)
20. DD Sarbassov SM Ali S Sengupta, et al. 2006 Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB Mol Cell 22 159 168 16603397 10.1016/j.molcel.2006.03.029 1:CAS:528:DC%2BD28Xkt1GmtLo%3D
21. RJ Motzer B Escudier S Oudard, et al. 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 449 456 18653228 10.1016/S0140-6736(08)61039-9 1:CAS:528:DC%2BD1cXps1GmsLY%3D
22. KWL Yee Z Zeng M Konopleva, et al. 2006 Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies Clin Cancer Res 12 17 5165 5173 16951235 10.1158/1078-0432.CCR-06-0764 1:CAS:528:DC%2BD28XovF2gsLc%3D (Pubitemid 44453345)
23. J Baselga V Semiglazov P van Dam, et al. 2009 Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer J Clin Oncol 27 16 2630 2637 19380449 10.1200/JCO.2008.18.8391 1:CAS:528:DC%2BD1MXnslWit7s%3D
24. MG Kris GJ Riely CG Azzoli, et al. 2007 Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial J Clin Oncol 25 18s 7575
25. T Kirkegaard A Naresh VS Sabine, et al. 2008 Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers Am J Pathol 129 5 735 743 10.1309/N6YB6YDVF58YCNHN
26. KS McCarty E Szabo JL Flowers, et al. 1986 Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors Cancer Res 46 4244s 4248s 3524805 (Pubitemid 16041242)
27. JJ Going 1994 Efficiently estimated histologic cell counts Hum Pathol 25 333 336 8163265 10.1016/0046-8177(94)90139-2 1:STN:280:DyaK2c3hsF2qsg%3D%3D (Pubitemid 24151116)
28. Sabine VS, Faratian D, Bartlett JMS (2008) Validation of cleaved caspase-3 antibody staining as a marker of apoptosis in breast cancer. Cancer Research Institute (NCRI) Cancer Conference 2008, 5-8 Oct 2008, Birmingham, UK. NCRI. Abstract C45. www.ncri.org.uk/ncriconference/2008abstracts/C45.html
29. T Kirkegaard J Edwards S Tovey LM McGlynn SN Krishna R Mukherjee, et al. 2006 Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48 7 787 794 16722926 10.1111/j.1365-2559. 2006.02412.x 1:STN:280:DC%2BD283ptleqsw%3D%3D (Pubitemid 43800937)
30. J Tabernero F Rojo E Calvo, et al. 2008 Dose- and Schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors J Clin Oncol 26 1603 1610 18332469 10.1200/JCO.2007.14.5482 1:CAS:528: DC%2BD1cXltlWiu7c%3D
31. A O'Donnell S Faivre HA Burris, et al. 2008 Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors J Clin Oncol 26 1588 1595 18332470 10.1200/JCO.2007.14.0988
32. MH Galea RW Blamey CE Elston IO Ellis 1992 The Nottingham Prognostic Index in primary breast cancer Breast Cancer Res Treat 22 207 219 1391987 10.1007/BF01840834 1:STN:280:DyaK3s%2FgsVyisA%3D%3D
33. M Dowsett I Smith SR Ebbs on behalf of the IMPACT Trialists 2005 Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival Clin Cancer Res 11 951s 958s 15701892 1:CAS:528:DC%2BD2MXislWns74%3D (Pubitemid 40111111)
34. G Viale A Giobbie-Hurder MM Regan, et al. 2008 Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole J Clin Oncol 28 5569 5575 10.1200/JCO.2008.17.0829
35. J Murray OE Young L Renshaw, et al. 2009 A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women Breast Cancer Res Treat 114 3 495 501 18438705 10.1007/s10549-008-0027-0 1:CAS:528:DC%2BD1MXisFSqt7s%3D
36. O Young L Renshaw EJ Macaskill, et al. 2008 Effects of fulvestrant 750 mg in premenopausal women with oestrogen-receptor-positive primary breast cancer Eur J Cancer 44 391 399 18083023 10.1016/j.ejca.2007.11.007 1:CAS:528: DC%2BD1cXhtl2isLg%3D
37. C Knuefermann Y Lu B Liu, et al. 2003 HER2/PI3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells Oncogene 22 3205 3212 12761490 10.1038/sj.onc.1206394 1:CAS:528:DC%2BD3sXjvFaksLo%3D (Pubitemid 36712932)
38. E Tokanuga A Kataoka Y Kimura, et al. 2006 The association between Akt activation and resistance to hormone therapy in metastatic breast cancer Eur J Cancer 42 629 635 10.1016/j.ejca.2005.11.025 (Pubitemid 43343685)
39. AS Clark K West S Streicher PA Dennis 2002 Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells Mol Cancer Ther 1 707 717 12479367 1:CAS:528: DC%2BD38XlsFSmtLk%3D
40. T Kirkegaard CJ Witton LM McGlynn, et al. 2005 Akt activation predicts outcome in breast cancer patients treated with tamoxifen J Pathol 207 139 146 16088978 10.1002/path.1829 1:CAS:528:DC%2BD2MXhtFKnsr7P (Pubitemid 41404144)
41. X Zhou M Tan VS Hawthorne, et al. 2004 Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers Clin Cancer Res 10 6779 6788 15501954 10.1158/1078-0432.CCR-04-0112 1:CAS:528:DC%2BD2cXpslGlt7c%3D (Pubitemid 39383026)
42. M Beeram QT Tan RR Tekmal, et al. 2007 Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling Ann Oncol 18 8 1323 1328 17693645 10.1093/annonc/mdm170 1:STN:280:DC%2BD2srptlyhtQ%3D%3D (Pubitemid 47305004)
43. OH Iwenofu RD Lackman AP Staddon, et al. 2008 Phospho-S6 ribosomal protein: a potential new predictive marker for targeted mTOR therapy Mod Pathol 21 231 237 18157089 10.1038/modpathol.3800995 1:CAS:528:DC%2BD1cXisVKmt7Y%3D (Pubitemid 351304283)
44. M Rosner N Siegel A Valli C Fuchs Hengstschlager 2010 mTOR phosphorylated at s2448 binds to raptor and rictor Amino Acids 38 1 223 228 19145465 10.1007/s00726-008-0230-7 1:CAS:528:DC%2BC3cXhtVehtrk%3D
45. D Generali SB Fox MP Brizzi, et al. 2008 Down-regulation of phosphatidylinositol 3-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer Clin Cancer Res 14 9 2673 2680 18451231 10.1158/1078-0432.CCR-07-1046 1:CAS:528: DC%2BD1cXlsV2qt7g%3D
46. VS Sabine J Ferguson N Thelwell, et al. 2009 Mutation of PI3KCA in post-menopausal with breast cancer and response to RAD001 treatment Cancer Res 69 Suppl 2 4063s 10.1158/0008-5472.SABCS-4063
47. CN Burge HR Chang SK Apple 2006 Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens Breast 15 167 172 16095904 10.1016/j.breast.2005.06.004 (Pubitemid 44268916)
48. S Iqbal TJ Anderson LP Marson, et al. 2002 MIB-1 assessments in breast cancers Breast 11 252 256 14965676 10.1054/brst.2002.0408 1:STN:280: DC%2BD2c%2Fns1Gqsg%3D%3D (Pubitemid 34830708)
49. P Bhat-Nakshatri G Wang H Appaiah, et al. 2008 AKT alters genome-side estrogen receptor alpha binding and impacts estrogen signaling in breast cancer Mol Cell Biol 28 24 7487 7503 18838536 10.1128/MCB.00799-08 1:CAS:528: DC%2BD1cXhsV2mtLbM
50. S Chan ME Scheulen S Johnston, et al. 2005 Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer J Clin Oncol 23 5314 5322 15955899 10.1200/JCO.2005.66.130 1:CAS:528:DC%2BD2MXpslOrtLo%3D (Pubitemid 46206985)
51. T Sorlie CM Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D (Pubitemid 32878711)